Submission of Board Meeting outcome.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Novelix Pharmaceuticals (formerly Trimurthi Ltd) reported strong audited financial results for FY2025-26 with revenue from operations jumping to Rs. 1,323.06 Cr from Rs. 307.19 Cr in the previous year, a staggering 331% increase driven by the company's shift to pharmaceutical bulk drugs business. PAT surged to Rs. 25.57 Cr from Rs. 1.07 Cr, representing 2,292% growth. The company allotted 28.10 lakh equity shares upon conversion of warrants at Rs. 20 each (face value Rs. 10 + premium Rs. 10), raising Rs. 4.22 Cr. Paid-up capital increased from Rs. 21.09 Cr to Rs. 23.90 Cr. The Board also re-appointed M/s VRPS & Co as Internal Auditors for FY 2026-27. Some agenda items including preferential securities issuance were deferred to a later meeting.
The massive revenue and profit growth signals successful business transformation, though existing shareholders face dilution from the warrant conversion. The negative operating cash flow of Rs. 22.59 Cr despite strong profitability indicates tight working capital management needs attention.